<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> are a group of hematopoietic disorders characterized by hematopoietic stem cell dysregulation and abnormalities in the immune system </plain></SENT>
<SENT sid="1" pm="."><plain>Mesenchymal stem cells (MSCs) and their derived stromal cells constitute a bone marrow microenvironment, which is the niche for hematopoiesis and a key compartment for immune development and regulation </plain></SENT>
<SENT sid="2" pm="."><plain>Existing evidence has shown that MSCs from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients have impaired capacity in supporting hematopoiesis </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we conducted an investigation to determine whether the immuno-modulatory function of MSCs is also impaired in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo>) patients </plain></SENT>
<SENT sid="4" pm="."><plain>METHOD: Flk1(+)CD31(-)CD34(-) MSCs were isolated from 15 MDS-RA patients and cultured for testing biological and immunological characteristics </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA patient-derived Flk1(+)CD31(-)CD34(-) MSCs showed <z:mpath ids='MPATH_458'>normal</z:mpath> <z:mp ids='MP_0000002'>morphology</z:mp>, phenotype and karyotype but appeared impaired in immuno-modulatory function </plain></SENT>
<SENT sid="6" pm="."><plain>The capacity of patient Flk1(+)CD31(-)CD34(-) MSCs to inhibit T lymphocyte activation and proliferation was impaired in vitro </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA patient-derived MSCs have impaired immuno-modulatory functions, suggesting that the dysregulation of hematopoiesis and immune response may originate from MSCs rather than <z:chebi fb="15" ids="50443">HSCs</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>MSCs might be a potential target for developing efficacious cures for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>